Dr. Alexander Fleming

Dr. Alexander (Zan) Fleming is Founder and Executive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, including gene and cell therapies, medical devices, and digital health technologies. Dr. Fleming founded in 2020 and heads the not-for-profit Kitalys Institute as a means of facilitating the testing, regulation, and commercialization of healthspan products. Kitalys also produces the annual Metabesity conference series, first held in London in 2017, which brings together global experts, policymakers, and advocates to catalyze progress towards equaling healthspan to lifespan. Zan received his B.S from the University of West Florida, his M.D. and internal medicine training from Emory and training in endocrinology at Vanderbilt. After 4 years at NIH, he went on to the US FDA to head clinical review of products for diabetes and other metabolic and endocrine disorders, growth and development, elevated lipids, and reproduction. His notable, but then controversial drug approvals, included the first statin and metformin. He was assigned to WHO at Geneva and represented FDA at other international initiatives.